NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies identified in the laboratories of Dr. Sachdev Sidhu at the University of Toronto and the laboratory of Dr. Joseph Schlessinger of Yale University. Dr. Sidhu is a member of the faculty of Donnelly Centre for Cellular and Biomolecular Research, and current director of the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto, as well as a member of the Kolltan Scientific Advisory Board. Terms of the license were not disclosed. The license coincided with an article published in the Proceedings of the National Academy of Sciences (PNAS) that reveals novel insights into the structural biology of the KIT receptor tyrosine kinase.
Help employers find you! Check out all the jobs and post your resume.
